PR Newswire (paid press release):
SARASOTA, Fla., Dec. 18, 2017 /PRNewswire/ — Lilac Corp announces a new design of its herpes website. The new design emphasizes the main benefit of Gene-Eden-VIR and Novirin: Stopping the herpes outbreaks. This benefit is one of the important results reported in recent clinical studies that tested the safety and efficacy of the two herbal treatments.
The clinical studies were carried out by Dr. Hanan Polansky, Dr. Edan Itzkovitz, and Adrian Javaherian from the Center for the Biology of Chronic Disease (CBCD). The studies followed the FDA guidelines for clinical studies. The studies were published in the medical journal Drug Design, Development and Therapy and the medical journal Clinical and Translational Medicine. Specifically, the studies showed that after 12 months of treatment, Gene-Eden-VIR and Novirin completely stopped the herpes outbreaks in 42% of the cases. In addition, the studies showed that in 73% of the cases, Gene-Eden-VIR and Novirin reduced the number of herpes outbreaks by more than 50%, and in 90.8% of the cases, Gene-Eden-VIR and Novirin either prevented or delayed the herpes outbreaks. The studies also showed that Gene-Eden-VIR and Novirin are better than acyclovir, valacyclovir, and famciclovir, the three leading drugs used in the treatment of genital herpes.  
TravelWireNews Chatroom for Readers (join us)
For more information on the clinical studies that tested the safety and efficacy of Gene-Eden-VIR/Novirin, visit http://cbcd.net/clinical-studies/. To order Gene-Eden-VIR or Novirin, visit: http://7hsv.com/
SOURCE: Lilac Corp
 Polansky H, Itzkovitz E, Javaherian A. Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases. Clin Transl Med. 2016 Dec;5(1):40. Epub 2016 Oct 20.
 Polansky H, Javaherian A, Itzkovitz E. Clinical study in genital herpes: natural Gene-Eden-VIR/Novirin versus acyclovir, valacyclovir, and famciclovir. Drug Des Devel Ther. 2016 Aug 29;10:2713-22
SOURCE Lilac Corp
Click here to read the full article.